US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Observe Medical ASA: Amendments to loan agreements with Navamedic ASA

Oslo, 15 November 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital situation. The Company has (as borrower) entered into two subordinated loan agreements with Navamedic ASA ("Navamedic") as lender for (i) a loan with an outstanding principal amount of NOK 32,000,000 plus accrued interest, entered into on 27 September 2019 ("Loan I") and (ii) a

Observe Medical – DOC (Declaration of Conformity) signed for UnoMeter[TM ]Safeti[TM] Plus and subscription form for equity investment received from industrial partner

Oslo, November 12[th], 2024 - Observe Medical ("the Company" or "Observe Medical") has today signed the DOC (Declaration of Conformity). This marks the final step for the establishment of a high-volume manufacturing platform for the UnoMeter™ product portfolio, consisting of UnoMeter™ 500 and UnoMeter™ Safeti™ Plus. The DOC is the final regulatory documentation that needs to be approved for the Observe Medical group to be able to accept and receive orders for UnoMeter™ Safeti™ Plus from customers and also accept other relevant commercial and financial commitments related thereto. The

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 26 August 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 1,000,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to purchase one share in the Company. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during

OBSERVE MEDICAL ASA: First half year report 2024

Oslo, August 26, 2024 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2024. Business update In the first half of 2024, Observe Medical achieved growth and market expansion of the UnoMeter™ portfolio. Observe Medical has achieved a major milestone with the early commercial launch of the UnoMeter™ Safeti Plus, marking significant strategic and commercial progress. This success highlights the effective collaboration between our product development team and external manufacturing partner. The launch underscores our commitment to

Observe Medical – First order from South America

Oslo, August 22, 2024 - Observe Medical ("the Company" or "Observe Medical") has received its first order of UnoMeter 500 products from a distributor in South America. This initial order represents a significant step towards expanding our footprint in a region that holds historical importance for the UnoMeter product line. This marks a significant milestone as we now have established sales networks across Europe, the Middle East, Asia, and South America, closely mirroring the extensive geographic reach previously achieved by Convatec. Jørgen Mann, CEO of Observe Medical, commented, "

Invitation to Observe Medical ASA's first half year 2024 presentation and Q&A

Oslo, August 19, 2024 - Observe Medical ("the Company" or "Observe Medical") will release its results for the first half year 2024 on Monday, 26 Augsut 2024. The presentation will be published on NewsWeb and the Company's website at 07:00 CET on the same day. The Company will host a presentation and Q&A session at 10:00 CET on the same day. Personal attendance is welcomed at Carnegie's offices at Aker Brygge, Fjordalleen 16. The session will also be streamed via webcast. To register and follow the presentation online, please copy and paste the following link into your browser, click

Jørgen Mann appointed permanent CEO of Observe Medical

Oslo, August 13, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces the appointment of Jørgen Mann as its permanent Chief Executive Officer (“CEO”). Having served as interim CEO since February 2024, Mr. Mann has proven his leadership capabilities and deep insight into the Company's strategic operations. The board is fully confident in his ability to steer Observe Medical into its next phase, focusing on commercial milestones, growth, and innovation. His leadership is expected to be crucial as the Company moves forward with its ambitious goals in the healthcare

Observe Medical ASA: Redelivery of lent shares to person closely associated with primary insider and mandatory notification of trade

Oslo, 6 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 17 July 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS in connection with tranche 2 of the private placement of new shares in the Company (the "Private Placement"). The share capital increase pertaining to tranche 2 of the Private Placement has now been registered, as announced by the Company yesterday, and the shares that were lent by Ingerø Reiten Investment Company AS have been

Observe Medical ASA: New share capital registered

Oslo, 5 August 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to raise gross proceeds of NOK 22 million (the "Private Placement"). The share capital increase pertaining to the issuance of 16,862,962 Offer Shares in the second tranche of the Private Placement (the "Tranche 2 Shares") has today been registered with the

Observe Medical announces Letter of Intent with Medical Imaging Company to explore Strategic Partnership for Biim Ultrasound

Oslo, 29 July 2024 – Observe Medical ASA ("the Company" or "Observe Medical") today announces a non-binding Letter of Intent (“LOI”) to explore a strategic partnership with a leading American medical imaging company (the "Partner Company"). The potential strategic partnership will contain a joint effort to develop and market handheld ultrasound-based solutions for the dialysis market and explore a potential distribution partnership within the EU. The Partner Company specializes in portable medical imaging solutions, backed by top-tier American Venture Capital and Investment Managers.

Allocation of offer shares to primary insiders and close associates, disclosure of share lending by person closely associated with a primary insider and mandatory notification of trade

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to raise gross proceeds of NOK 22 million (the "Private Placement"). As mentioned in the announcement, the completion of tranche 2 of the Private Placement  ("Tranche 2") was inter alia subject to the extraordinary general meeting of the Company (the "EGM")

Observe Medical ASA: Extraordinary general meeting held on 17 July 2024

Oslo, 17 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 26 June 2024, regarding notice of an extraordinary general meeting in connection with a private placement and contemplated subsequent offering in the Company. The extraordinary general meeting was held today, on 17 July 2024, at 14.00 hours (CEST). All resolutions proposed by the board of directors were approved, including (i) the issuance of 16,862,962 offer shares to complete tranche 2 of the private placement, (ii) granting the

Observe Medical ASA: Redelivery of lent shares to persons closely associated with primary insiders and mandatory notification of trade

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024 (the "Announcement"), regarding share lending by Ingerø Reiten Investment Company AS and ELI AS(jointly the "Share Lenders")in connection with the private placement of new shares in the Company (the "Private Placement"). The share capital increase pertaining to tranche 1 of the Private Placement has now been registered, as announced by the Company earlier today, and the shares that were lent by each of the Share Lenders

Observe Medical ASA: New share capital registered

Oslo, 2 July 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of 55,000,000 new shares in the Company (the "Offer Shares") at a subscription price of NOK 0.40 per Offer Share to raise gross proceeds of NOK 22 million (the "Private Placement"). The share capital increase pertaining to the issuance of 38,137,038 Offer Shares in the first tranche of the Private Placement has today been registered with the Norwegian Register of

Observe Medical ASA: Notice of extraordinary general meeting on 17 July 2024 in connection with the private placement and a contemplated subsequent offering

Oslo, 26 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement"). In connection with completion of the Private Placement and a contemplated subsequent offering, the Company hereby calls for an extraordinary general meeting to be held on 17 July 2024 at 14:00 hours (CEST). The extraordinary general meeting will be held as a physical

Observe Medical ASA – Participation in the Private Placement by Primary Insiders and their Close Associates

Oslo, 25 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") yesterday, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement"). The Company is in this respect pleased to announce that members of the board of directors and members of the management or their close associates have been allocated shares in the Private Placement, as set out below:

Observe Medical ASA: Ex. Subsequent Offering today

OBSRV – EX. SUBSEQUENT OFFERING TODAY Issuer name: Observe Medical ASA Ex. date: 25 June 2024 Type of corporate action: Subsequent offering/repair issue Additional information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 24 June 2024 with key information relating to the subsequent offering.   This information is published in accordance with the requirements of the Continuing Obligations.

Observe Medical ASA: Key information relating to subsequent offering _ repair issue

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today, regarding the placement of a private placement (the "Private

Observe Medical ASA: Disclosure of share lending by persons closely associated with primary insiders and mandatory notification of trade

Oslo, 24 June 2024 Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today (the "Announcement"), regarding the private placement of new shares in the Company (the "Private Placement"). As further described in the Announcement, the Private Placement consists of two tranches, of which tranche 1 comprises 38,137,038 offer shares ("Tranche 1") and tranche 2 comprises 16,862,962 offer shares ("Tranche 2"), the latter subject to a resolution by the extraordinary general meeting of the Company to issue

Observe Medical ASA: Potential equity investment from the group's largest partner within manufacturing and supply of urine measurement products

Oslo, 24 June 2024 Reference is made to the announcement made by Observe Medical ASA (the "Company" or "Observe Medical", and, together with its subsidiaries, the "Group", OSE ticker "OBSRV") earlier today, on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement"). The Company is in this respect pleased to announce that Jiangsu Hongxin Medical Technology Co., Ltd ("Jiangsu Hongxin"), the Group's largest partner within the manufacturing and supply of urine measurement products,

Observe Medical ASA: Placement of NOK 22 million Private Placement and contemplated Subsequent Offering

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 24 June 2024 Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") today announces that the Company has successfully placed a private placement of NOK 22 million with a group of existing shareholders,

Observe Medical ASA announces Letter of Intent with Sulacare for Female Catheterization Product Launch

Oslo, 4 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") announces that it has entered into a Letter of Intent (LOI) with Sulacare AS ("Sulacare") to collaborate on the commercial launch of Sulacare's innovative and proprietary female catheterization product. This partnership goes beyond leveraging Observe Medical’s established platform to commercialize and distribute innovative high-quality MedTech products through its global distribution network. It creates a strategic fit with Observe Medical's existing product portfolio, particularly the UnoMeter™. Since the

Observe Medical provides update on strong UnoMeter[TM] momentum in UK and Irish markets

Oslo, 3 June 2024 – Observe Medical ASA ("the Company" or "Observe Medical") continues to see positive momentum in the re-adoption of its UnoMeter™ brand of medical devices into NHS and across private hospitals in the United Kingdom and Ireland.   Building on previous announcements, Observe Medical confirms that since the start of 2024, UnoMeter™ products have been delivered to over 30 hospitals within 11 NHS Trusts in England. UnoMeter™ 500 (urinemeter) and UnoMeter™ Abdopressure™ (IAP) are experiencing strong demand, further solidified by their inclusion on both the English and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe